Differences in disease stage in the human cohorts studied (advanced NASH with fibrosis vs. NAFLD), could partly explain differential expression of NKG2D and circulating NK cell frequency. Here, KLRK1 is linked to metabolic dysfunction-associated steatohepatitis.